MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-101242-PIP01-23-M01

Scope of the Application

Active Substance(s)

LUMASIRAN SODIUM

Condition(s)

Treatment of hyperoxaluria.

Pharmaceutical Form(s)

Solution for injection

Route(s) of Administration

SUBCUTANEOUS USE

Name / Corporate name of the PIP applicant

Alnylam UK

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Alnylam UK submitted to the licensing authority on 02/11/2023 14:24 GMT an application for a Modification

The procedure started on 09/07/2024 15:26 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-101242-PIP01-23-M01

Of 17/07/2024 09:45 BST

On the adopted decision for LUMASIRAN SODIUM (MHRA-101242-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for LUMASIRAN SODIUM, Solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Alnylam UK, Braywick Gate, Braywick Rd, Maidenhead, UNITED KINGDOM, SL61DA

ANNEX I

1. Waiver

1.1 Condition:

Not applicable.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of hyperoxaluria.

2.2 Indication(s) targeted by the PIP:

All subsets of the paediatric population from birth to less than 18 years of age.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

All subsets of the paediatric population from birth to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Solution for injection.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Study 1 deleted during procedure MHRA-101242-PIP01-23-M01
Non-Clinical Studies	1	Study 2 (8335749 / GO1-GLP15-043) 4-week dose range-finding toxicity study in neonate and juvenile rats.
Clinical Studies	5	Study 3 (ALN-G01-001 (2015-004407-23)) Single (subject/ patient) blind, randomised, placebo controlled trial to evaluate safety, tolerability pharmacokinetics and pharmacodynamics of ALN-GO1 in healthy adult subjects, and patients (children from 6 years of age (and adults) with primary hyperoxaluria type 1 (PH1)). Study 4 Open-label extension study for patients who previously participated in ALN-GO1 clinical studies including Study 3 (ALN-GO1-001), Study 5 (ALN-GO1-003) and Study 6 (ALN-GO1-004). Study 5 (ILLUMINATE-A; ALN-GO1-003) Double-blind, randomised, placebo controlled study with an extended dosing period to evaluate efficacy, safety, pharmacokinetics and pharmacodynamics of ALN-GO1 in children from 6 years of age (and adults) with primary hyperoxaluria type 1 (PH1) and relatively intact renal function. Study 6 (ILLUMINATE B; ALN-GO1-004) Open-label, uncontrolled trial to evaluate safety, pharmacokinetics

		and pharmacodynamics of ALN-GO1 in children from birth to less than 6 years of age with primary hyperoxaluria type 1 (PH1) and relatively intact renal function. Study 7 (ILLUMINATE C; ALN-GO1-005) Open-label, uncontrolled trial to evaluate safety, pharmacokinetics and pharmacodynamics of ALN-GO1 in children from birth to less than 18 years of age (and adults) with primary hyperoxaluria type 1 (PH1) and advanced renal disease including those on dialysis.
Extrapolation, Modeling & Simulation Studies	2	Study 8 (ALN-GO1-MS1) Modelling and simulation study to evaluate the use of the product and support dose selection for the treatment of primary hyperoxaluria type 1 (PH1) in children from 6 years of age with relatively intact renal function. Study 9 (ALN-GO1-MS2) Modelling and simulation study to evaluate the use of the product and support dose selection for the treatment of primary hyperoxaluria type 1 (PH1) in children from birth to less than 6 years of age.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/10/2025
Deferral of one or more studies contained in the paediatric investigation plan:	Yes